There is still time to recognise outstanding contributions to CML research and patient management with one of the three 2025 iCMLf Prizes.
🥇 The Rowley Prize – For groundbreaking contributions to CML biology.
🥇 The Goldman Prize – Recognising transformative advancements in CML patient care.
🥇 The iCMLf Prize – Highlighting exceptional efforts to overcome CML treatment challenges in low- and middle-income countries.
2025 is a remarkable milestone in the fight against chronic myeloid leukemia - the 25th anniversary of tyrosine kinase inhibitors (TKIs). The story of TKI development is one of collaboration and courage. A story that formed the basis of the iCMLf, and one that we hope to emulate as we continue working to improve outcomes for people with CML.
Over the coming year we will share highlights of the development, impact and future opportunities of this incredible therapy. To begin, we share a message from Professor Jorge Cortes and Professor Brian Druker.